258 related articles for article (PubMed ID: 31267199)
1. Microfluidic-based immunohistochemistry for breast cancer diagnosis: a comparative clinical study.
Aimi F; Procopio MG; Alvarez Flores MT; Brouland JP; Piazzon N; Brajkovic S; Dupouy DG; Gijs M; de Leval L
Virchows Arch; 2019 Sep; 475(3):313-323. PubMed ID: 31267199
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
3. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
Stevanovic L; Choschzick M; Moskovszky L; Varga Z
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
5. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
6. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR.
Caselli E; Pelliccia C; Teti V; Bellezza G; Mandarano M; Ferri I; Hartmann K; Laible M; Sahin U; Varga Z; Lupi C; Stracci F; Sidoni A
PLoS One; 2021; 16(9):e0255580. PubMed ID: 34555047
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
8. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
10. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
11. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
Park MM; Ebel JJ; Zhao W; Zynger DL
Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
[TBL] [Abstract][Full Text] [Related]
13. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
14. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer.
Bjerre C; Knoop A; Bjerre K; Larsen MS; Henriksen KL; Lyng MB; Ditzel HJ; Rasmussen BB; Brünner N; Ejlertsen B; Laenkholm AV
Acta Oncol; 2013 Jan; 52(1):82-90. PubMed ID: 23205744
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens.
Hariri N; Hasteh F; Walavalkar V; Roma AA; Fadare O
Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):1-7. PubMed ID: 28549033
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
18. Core needle biopsy as an alternative to whole section in IHC4 score assessment for breast cancer prognostication.
Liu M; Tang SX; Tsang JYS; Shi YJ; Ni YB; Law BKB; Tse GMK
J Clin Pathol; 2018 Dec; 71(12):1084-1089. PubMed ID: 30228212
[TBL] [Abstract][Full Text] [Related]
19. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
[TBL] [Abstract][Full Text] [Related]
20. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
